Northwest Biotherapeutics (NWBO) Equity Average (2016 - 2025)
Northwest Biotherapeutics (NWBO) has 15 years of Equity Average data on record, last reported at -$104.5 million in Q3 2025.
- For Q3 2025, Equity Average fell 33.47% year-over-year to -$104.5 million; the TTM value through Sep 2025 reached -$104.5 million, down 33.47%, while the annual FY2024 figure was -$80.1 million, 17.34% up from the prior year.
- Equity Average reached -$104.5 million in Q3 2025 per NWBO's latest filing, down from -$99.9 million in the prior quarter.
- Across five years, Equity Average topped out at -$58.5 million in Q2 2023 and bottomed at -$358.1 million in Q1 2021.
- Average Equity Average over 5 years is -$136.4 million, with a median of -$99.9 million recorded in 2025.
- Peak YoY movement for Equity Average: crashed 777.26% in 2021, then soared 69.82% in 2022.
- A 5-year view of Equity Average shows it stood at -$212.9 million in 2021, then soared by 44.34% to -$118.5 million in 2022, then soared by 42.67% to -$67.9 million in 2023, then dropped by 28.54% to -$87.3 million in 2024, then fell by 19.72% to -$104.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were -$104.5 million in Q3 2025, -$99.9 million in Q2 2025, and -$97.0 million in Q1 2025.